NASDAQ:AGTC Applied Genetic Technologies - AGTC Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Applied Genetic Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$0.39▼$0.3950-Day Range$0.37▼$0.4252-Week Range$0.23▼$2.83VolumeN/AAverage Volume943,490 shsMarket Capitalization$26.62 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Applied Genetic Technologies MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside1,763.1% Upside$7.33 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.65) to ($0.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.47 out of 5 starsMedical Sector968th out of 1,048 stocksBiological Products, Except Diagnostic Industry158th out of 168 stocks 3.1 Analyst's Opinion Consensus RatingApplied Genetic Technologies has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.33, Applied Genetic Technologies has a forecasted upside of 1,763.1% from its current price of $0.39.Amount of Analyst CoverageApplied Genetic Technologies has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AGTC. Previous Next 0.0 Dividend Strength Dividend YieldApplied Genetic Technologies does not currently pay a dividend.Dividend GrowthApplied Genetic Technologies does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApplied Genetic Technologies has received a 50.98% net impact score from Upright. Applied Genetic Technologies seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is driven by its "Preclinical research services for physical health" and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Applied Genetic Technologies is -0.62. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for AGTC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Applied Genetic Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Applied Genetic Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Applied Genetic Technologies is held by insiders.Percentage Held by InstitutionsOnly 22.05% of the stock of Applied Genetic Technologies is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Applied Genetic Technologies are expected to decrease in the coming year, from ($0.65) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Genetic Technologies is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Genetic Technologies is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApplied Genetic Technologies has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Applied Genetic Technologies (NASDAQ:AGTC) StockApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.Read More Receive AGTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address AGTC Stock News HeadlinesJanuary 5, 2023 | thestreet.comApplied Genetic Technologies (AGTC) Stock Climbs on $124 Million Biogen DealNovember 28, 2022 | finance.yahoo.com*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*January 26, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. November 22, 2022 | finance.yahoo.com*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*November 15, 2022 | finance.yahoo.comApplied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022November 3, 2022 | finance.yahoo.comApplied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022October 25, 2022 | finance.yahoo.comFlorida investment firm looks to take Cambridge gene therapy startup privateOctober 24, 2022 | lse.co.ukSyncona to acquire retinal therapy firm Applied Genetic TechnologiesJanuary 26, 2023 | PressReach (Ad)Stocks News AnnouncementDon't miss this update. Read the press release about Small Pharma.October 23, 2022 | finance.yahoo.comSyncona to Acquire Applied Genetic Technologies CorporationOctober 18, 2022 | markets.businessinsider.comiNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesisSeptember 30, 2022 | msn.comHC Wainwright & Co. Maintains Buy Rating for Applied Genetic: Here's What You Need To KnowSeptember 23, 2022 | fool.comApplied Genetic Technologies (NASDAQ: AGTC)August 29, 2022 | reuters.comApplied Genetic Technologies CorpJuly 26, 2022 | finance.yahoo.comAGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing FacilityJuly 13, 2022 | finance.yahoo.comAGTC Announces Pricing of $10 Million Underwritten Public OfferingJuly 12, 2022 | finance.yahoo.comAGTC Announces Proposed Underwritten Public OfferingJune 8, 2022 | finance.yahoo.comAGTC Announces Key Appointments to Leadership TeamJune 6, 2022 | finance.yahoo.comAGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual MeetingMay 18, 2022 | finance.yahoo.comAGTC to Present at the H.C. Wainwright Global Investment ConferenceMay 16, 2022 | finance.yahoo.comAGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis PigmentosaMay 10, 2022 | finance.yahoo.comAGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building’s Structural CompletionMay 4, 2022 | finance.yahoo.comPositive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual MeetingMay 2, 2022 | tmcnet.comAGTC to Present Preclinical Research Supporting Gene TherapyMay 2, 2022 | finance.yahoo.comAGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell TherapyApril 14, 2022 | finance.yahoo.comAGTC to Present at Cell & Gene Meeting on the MediterraneanMarch 22, 2022 | finance.yahoo.comAGTC Announces Pricing of Public Offering of Common StockSee More Headlines Receive AGTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address AGTC Company Calendar Last Earnings11/09/2021Today1/26/2023Next Earnings (Estimated)2/13/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGTC CUSIPN/A CIK1273636 Webwww.agtc.com Phone(386) 462-2204FaxN/AEmployees83Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.33 High Stock Price Forecast$16.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+662.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,940,000.00 Net MarginsN/A Pretax Margin-21,537.54% Return on Equity-192.90% Return on Assets-92.54% Debt Debt-to-Equity Ratio0.39 Current Ratio1.40 Quick Ratio1.40 Sales & Book Value Annual Sales$320,000.00 Price / Sales83.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book1.51Miscellaneous Outstanding Shares67,632,000Free Float64,859,000Market Cap$26.62 million OptionableOptionable Beta1.55 Key ExecutivesMs. Susan B. Washer (Age 61)Pres, CEO & Director Comp: $747.84kMr. Jonathan I. Lieber M.B.A. (Age 52)Chief Financial Officer Comp: $533.14kDr. Susan Schneider M.D. (Age 64)Chief Medical Officer Comp: $480.32kDr. Nicholas MuzyczkaCo-FounderDr. Barry J. Byrne M.D.Ph.D., Co-FounderDr. William W. HauswirthCo-Founder & Member of Ophthalmology Scientific Advisory BoardDr. Richard Jude Samulski Ph.D.Co-FounderDr. Terence R. Flotte M.D.Co-FounderMr. Gerald Anthony ReynoldsChief Accounting Officer, Principal Accounting Officer & TreasurerDr. Abraham Scaria Ph.D. (Age 63)Chief Scientific Officer More ExecutivesKey CompetitorsIdera PharmaceuticalsNASDAQ:IDRACASI PharmaceuticalsNASDAQ:CASIEntera BioNASDAQ:ENTXQuince TherapeuticsNASDAQ:QNCXCodiak BioSciencesNASDAQ:CDAKView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 503,929 shares on 11/15/2022Ownership: 2.185%Colony Group LLCBought 112,332 shares on 11/15/2022Ownership: 0.654%Citadel Advisors LLCBought 404,809 shares on 11/15/2022Ownership: 0.627%Price T Rowe Associates Inc. MDSold 153,375 shares on 11/15/2022Ownership: 0.161%Two Sigma Advisers LPBought 60,700 shares on 11/15/2022Ownership: 0.155%View All Insider TransactionsView All Institutional Transactions AGTC Stock - Frequently Asked Questions Should I buy or sell Applied Genetic Technologies stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AGTC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGTC, but not buy additional shares or sell existing shares. View AGTC analyst ratings or view top-rated stocks. What is Applied Genetic Technologies' stock price forecast for 2023? 8 equities research analysts have issued 12-month price objectives for Applied Genetic Technologies' shares. Their AGTC share price forecasts range from $3.00 to $16.00. On average, they expect the company's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 1,763.1% from the stock's current price. View analysts price targets for AGTC or view top-rated stocks among Wall Street analysts. When is Applied Genetic Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023. View our AGTC earnings forecast. How were Applied Genetic Technologies' earnings last quarter? Applied Genetic Technologies Co. (NASDAQ:AGTC) released its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. During the same period in the prior year, the company posted ($0.60) EPS. What other stocks do shareholders of Applied Genetic Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Micron Technology (MU), VBI Vaccines (VBIV), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Anavex Life Sciences (AVXL), Galmed Pharmaceuticals (GLMD) and Genocea Biosciences (GNCA). What is Applied Genetic Technologies' stock symbol? Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC." What is Applied Genetic Technologies' stock price today? One share of AGTC stock can currently be purchased for approximately $0.39. How much money does Applied Genetic Technologies make? Applied Genetic Technologies (NASDAQ:AGTC) has a market capitalization of $26.62 million and generates $320,000.00 in revenue each year. The biotechnology company earns $-68,940,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. How can I contact Applied Genetic Technologies? Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The official website for the company is www.agtc.com. The biotechnology company can be reached via phone at (386) 462-2204 or via email at david.carey@finnpartners.com. This page (NASDAQ:AGTC) was last updated on 1/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.